This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
This is a list of Roman legions, including key facts about each legion, primarily focusing on the Principate (early Empire, 27 BC – 284 AD) legions, for which there exists substantial literary, epigraphic and archaeological evidence.
== Immunity == Immune cells can be divided into myeloid cells and lymphoid cells. Myeloid cells, including macrophages and neutrophils, are especially implicated in the respiratory burst. They are phagocytic, and the respiratory burst is vital for the subsequent degradation of internalised bacteria or other pathogens. This is an important aspect of the innate immunity. Respiratory burst requires a 10 to 20 fold increase in oxygen consumption through NADPH oxidase (NOX2 in humans) activity. NADPH is the key substrate of NOX2, and bears reducing power. Glycogen breakdown is vital to produce NADPH. This occurs via the pentose phosphate pathway. The NOX2 enzyme is bound in the phagolysosome membrane. Post bacterial phagocytosis, it is activated, producing superoxide via its redox centre, which transfers electrons from cytosolic NADPH to O2 in the phagosome.
The P-site (for peptidyl) is the second binding site for tRNA in the ribosome. The other two sites are the A-site (aminoacyl), which is the first binding site in the ribosome, and the E-site (exit), the third. During protein translation, the P-site holds the tRNA which is linked to the growing polypeptide chain. When a stop codon is reached, the peptidyl-tRNA bond of the tRNA located in the P-site is cleaved releasing the newly synthesized protein. During the translocation step of the elongation phase, the mRNA is advanced by one codon, coupled to movement of the tRNAs from the ribosomal A to P and P to E sites, catalyzed by elongation factor EF-G.
=== Expansion === In March 2020, many of the Cane's locations switched from dine-in to pick-up and take-out service only due to the COVID-19 pandemic, whereas others closed temporarily. As of July 2020, certain locations had reopened their dining rooms, although Graves said the company was in no rush to do so on a full scale. In 2021, in response to a shortage of workers at the time, the company began dispatching hundreds of its corporate employees to work in its restaurants as cooks and cashiers, in addition to their existing duties regarding the hiring of new employees. The company planned to hire 10,000 new employees. The company's co-CEO said that the corporate employees are trained in the kitchen and on the register under normal circumstances. In 2022, Raising Cane's sued a shopping center in Hobart, Indiana. After the restaurant chain had signed a long-term lease, it was revealed that the shopping center had a non-compete agreement with McDonald's which prohibited other vendors from selling de-boned chicken products in the complex. On June 27, 2023, Raising Cane's opened up their first New York location in Times Square.
Sources: en.wikipedia.org
==== Open Roof Deformity ==== Reduction of a dorsal hump may involve bone (upper vault) and/or cartilage (middle vault). When the bony dorsum (eg, nasal bone) is reduced, there may be a resulting gap in the middle of the nasal bones. This is typically corrected intraoperatively with lateral osteotomies to narrow the nasal bones and remove the gap. However, if the gap is not corrected, then an open roof deformity may result.
Nicotinamide riboside kinase 1 is an enzyme that in humans is encoded by the NMRK1 gene. As both a nicotinate riboside kinase (EC 2.7.1.173), and a ribosylnicotinamide kinase (EC 2.7.1.22), this enzyme helps perform a step in the process of converting certain forms of niacin/Vitamin B3 into active coenzymes like NAD+. In humans, nicotinamide riboside kinase 1 is expressed in most tissues of the body, compared to the other isozyme, nicotinamide riboside kinase 2, which is predominantly found in muscles.
A lack of accurate data makes it difficult to document numerically the extent of the human losses suffered by Polish citizens during World War II. Additionally, many assertions made in the past must be considered suspect due to flawed methodology and a desire to promote certain political agendas. The last available enumeration of ethnic Poles and the large ethnic minorities is the Polish census of 1931. Exact population figures for 1939 are therefore not known. According to the United States Holocaust Memorial Museum, at least 3 million Polish Jews and at least 1.9 million non-Jewish Polish civilians were killed. According to the historians Brzoza and Sowa, about 2 million ethnic Poles were killed, but it is not known, even approximately, how many Polish citizens of other ethnicities perished, including Ukrainians, Belarusians, and Germans. Millions of Polish citizens were deported to Germany for forced labor or to German extermination camps such as Treblinka, Auschwitz and Sobibór. Nazi Germany intended to exterminate the Jews completely, in actions that have come to be described collectively as the Holocaust. The Poles were to be expelled from areas controlled by Nazi Germany through a process of resettlement that started in 1939. Such Nazi operations matured into a plan known as the Generalplan Ost that amounted to displacement, enslavement and partial extermination of the Slavic people and was expected to be completed within 15 years.
Sources: en.wikipedia.org
=== 31 May === At least 89 people were killed in an SAF airstrike on a market in Al-Koma, North Darfur. At least 13 people were killed in RSF attacks on West and South Kordofan. The SAF launched drone strikes on Nyala.
== History of profession == The idea of physician extenders was conceived in 1966 by physician-educator Eugene A. Stead at Duke University, where the first physician assistant program was established. Three years later, also at Duke, Chairman of Pathology, Dr. Thomas Kinney established the first pathologists’ assistant program. As of June 2025, seventeen accredited programs have been established across the United States and Canada and six others are in various stages of accreditation.
==== Types of protectants ==== Acetals and Ketals – Removed by acid. Normally, the cleavage of acyclic acetals is easier than of cyclic acetals. Acylals – Removed by Lewis acids. Dithianes – Removed by metal salts or oxidizing agents.
Ethanol is produced naturally as a byproduct of the metabolic processes of yeast and hence is present in any yeast habitat, including even endogenously in humans, but it does not cause raised blood alcohol content as seen in the rare medical condition auto-brewery syndrome (ABS). It is manufactured through hydration of ethylene or by brewing via fermentation of sugars with yeast (most commonly Saccharomyces cerevisiae). The sugars are commonly obtained from sources like steeped cereal grains (e.g., barley), grape juice, and sugarcane products (e.g., molasses, sugarcane juice). Ethanol–water mixture which can be further purified via distillation.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.